As GLP-1 medications including Wegovy, Ozempic, Mounjaro and Zepbound reshape diabetes and weight loss care, recent developments such as new partnerships, safety questions and challenges in patient persistence show the landscape is quickly changing.  Here are five recent GLP-1 developments: …

The American Hospital Association and three other healthcare organizations have filed an amicus brief defending Tennessee’s 340B contract pharmacy law, which is facing a challenge from the pharmaceutical industry.  Here are three notes: 

Standard first-line drug therapies for the treatment of bone density disorders have been linked to higher risk of experiencing a cardiovascular event, according to a study published June 26 in Epic Research. Here are five notes on the study: Read…

The U.S. Supreme Court declined to review a 2023 ruling by the 10th U.S. Circuit Court of Appeals striking down provisions of an Oklahoma law regulating pharmacy benefit managers, The Journal Record reported June 30.  The high court’s denial lets…

The FDA now requires updated labeling for all extended-release stimulant medications used to treat attention deficit hyperactivity disorder, warning of increased risk of weight loss and other side effects in children younger than 6.  Though extended release tablets such as…

The dermatology market in the U.S. is at a pivotal moment of transformation, with spending poised to climb from $40.55 billion in 2023 to $70 billion by 2030. This unprecedented growth mirrors past instances where blockbuster therapies revolutionized treatment for…

Boise, Idaho-based St. Luke’s Health System has launched outbound pharmacy delivery from its new Consolidated Service Center, centralizing medication distribution to 14 acute care and St. Luke’s Cancer Institute pharmacy locations as of June 19. The rollout marks the first…

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory approval and advancing the combo flu and COVID shot, CNBC reported June…

The FDA has eliminated Risk Evaluation and Mitigation Strategies for all currently approved BCMA- and CD19-directed autologous CAR-T cell immunotherapies, determining that the safety program is no longer necessary to ensure the benefits of the therapies outweigh the risks.  The…

UnitedHealth Group’s Optum Rx will remove reauthorization requirements for more than 60 chronic disease medications on July 1.  The cuts are in addition to about 80 reauthorizations Optum Rx eliminated in March, which the company said will increase medication accessibility…